PSMA PET is well established as being superior to conventional imaging for staging, recurrence detection, patient-selection and planning for peptide receptor radioligand therapy (PRLT), and post-therapy response assessment in PCa [5, 10–15]. The gene discussed is FOLH1; the disease is posterior cortical atrophy.